Codexis Advances RNA Manufacturing Platform
Analysis based on 6 articles · First reported May 20, 2026 · Last updated May 20, 2026
The advancements by Codexis in RNA therapeutic manufacturing, particularly in stereochemical control and enzymatic synthesis, are expected to positively impact the biotechnology and pharmaceutical sectors. These innovations could lead to more efficient and sustainable production of RNAi therapeutics, potentially increasing the efficacy and accessibility of these drugs, which would benefit companies like Codexis and the broader market.
Codexis, a leading provider of enzymatic solutions, announced significant advancements in its ECO Synthesis Manufacturing Platform for RNA therapeutic manufacturing at TIDES USA 2026. The company presented new data demonstrating full-length siRNA synthesis with precise control of phosphorothioate stereochemistry, a crucial factor for optimizing drug potency and quality. Additionally, Codexis revealed the platform's new ability to initiate enzymatic RNA synthesis from a single nucleotide, eliminating the need for chemically-synthesized starter oligonucleotides and enhancing efficiency. These innovations address key industry challenges in scalability and sustainability, with the ECO Synthesis platform showing over a 50% reduction in global warming potential compared to conventional methods. Drug development leaders from Corsera Health, Arrowhead Pharmaceuticals, and Wave Life Sciences participated in a panel, affirming the increasing importance of stereochemical control in advancing next-generation RNA therapeutics. Alison Moore, President and CEO, and Stefan Li, CSO of Codexis, highlighted the potential for improved drug administration options and environmental efficiency.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard